India to United Kingdom: Amikacin Export Trade Route

To import finished pharmaceutical formulations containing Amikacin into the United Kingdom, compliance with the Medicines and Healthcare products Regulatory Agency (MHRA) regulations is mandatory. The key requirements include:

1. Marketing Authorisation (MA): An MA is essential for the legal sale and supply of medicinal products in the UK. The application must be submitted in the Common Technical Document (CTD) or electronic CTD (eCTD) format, encompassing comprehensive data on quality, safety, and efficacy. Approval timelines can vary, typically ranging from 12 to 24 months, depending on the complexity of the application and the completeness of the submitted data. Specific fees are associated with the application process; applicants should consult the MHRA's current fee structure for precise amounts.

2. Manufacturer's Licence (ML): Importers must hold a valid ML, authorizing the importation of medicinal products. This licence ensures that imported products meet UK standards and are manufactured in compliance with Good Manufacturing Practice (GMP).

3. Good Manufacturing Practice (GMP) Compliance: Indian manufacturing facilities producing Amikacin formulations must comply with GMP standards equivalent to those in the UK. The MHRA may conduct inspections of these facilities to verify compliance. The frequency and scheduling of inspections are risk-based and can be influenced by factors such as the facility's compliance history and the criticality of the products manufactured.

4. Import Notification: For unlicensed medicines, importers are required to notify the MHRA of their intent to import. The MHRA assesses these notifications and may issue an objection within 28 days. In urgent clinical situations, the MHRA can expedite this process, potentially providing a response within two working days. Importers must submit a completed notification form along with evidence of GMP compliance and clinical need. Incomplete notifications may be rejected. (gov.uk)

Indian exporters of Amikacin formulations must adhere to stringent GMP standards to supply the UK market. Key requirements include:

1. GMP Certification: Manufacturing facilities must obtain GMP certification from the MHRA or an equivalent regulatory authority recognized by the UK. This certification confirms that the facility complies with international manufacturing standards.

2. Supplier Qualification: All active pharmaceutical ingredients (APIs), excipients, and packaging materials must be sourced from qualified suppliers with documented GMP compliance. The qualification process includes pre-screening, on-site audits, quality agreements, and continuous monitoring. Critical materials may require testing of multiple supplier lots before qualification and regular on-site audits.

3. Recent Inspections: The MHRA maintains a database of GMP certificates and non-compliance reports. For instance, as of February 2021, Dr. Reddy's Laboratories Limited in Srikakulam, India, held a GMP certificate issued by the MHRA. Manufacturers should regularly consult the MHRA's database to ensure their compliance status is current. (cms.mhra.gov.uk)

Several regulatory changes between 2024 and 2026 have impacted Indian pharmaceutical exports to the UK:

1. Revised GMP Regulations in India: On January 6, 2024, India's Ministry of Health published revised regulations under Annex M of the Drugs and Cosmetics Rules. These revisions align India's GMP standards with global benchmarks, including those of the World Health Organization (WHO). Key changes include the introduction of a pharmaceutical quality system (PQS), quality risk management (QRM), product quality review (PQR), and validation of equipment. The term 'Good Manufacturing Practices' was replaced with 'Good Manufacturing Practices and Requirements of Premises, Plant and Equipment for Pharmaceutical Products.'

2. MHRA GMP Certification Updates: In November 2025, the MHRA issued updated GMP certificates to Piramal Pharma Solutions' facility in Grangemouth, UK, following a successful compliance report and desktop inspection. These certificates cover all activities within the facility's Helix building, including its supporting warehouse and laboratory areas, and are valid for three years.

3. MHRA GMP Certification for WuXi Biologics: In January 2026, WuXi Biologics announced that two of its manufacturing facilities in Wuxi, China, received GMP certifications from the UK MHRA for the commercial manufacturing of an ophthalmic biologic. The facilities successfully passed MHRA's assessment with no critical findings, reaffirming WuXi Biologics' robust quality and compliance systems.

These developments underscore the importance of adhering to updated GMP standards and maintaining compliance with both Indian and UK regulatory requirements to ensure uninterrupted access to the UK market.

Amikacin, an aminoglycoside antibiotic, is primarily utilized in the treatment of severe bacterial infections, including those caused by multidrug-resistant strains. The demand for Amikacin formulations in the United Kingdom is influenced by factors such as the prevalence of hospital-acquired infections, the aging population, and the National Health Service's (NHS) commitment to providing comprehensive healthcare coverage.

In the fiscal year 2024-2025, the United Kingdom's healthcare expenditure continued to rise, reflecting increased investments in medical treatments and pharmaceuticals. While specific data on the domestic production of Amikacin formulations is limited, the United Kingdom relies on both domestic manufacturing and imports to meet its pharmaceutical needs. The importation of Amikacin formulations, including those from India, plays a crucial role in ensuring a steady supply of this essential antibiotic.

Pharmaceutical products falling under HS code 30049099, which includes Amikacin formulations, are subject to a 0% Most-Favored-Nation (MFN) import duty rate in the United Kingdom. This exemption aligns with the United Kingdom's policy to facilitate access to essential medicines. Additionally, there are no anti-dumping duties imposed on pharmaceutical imports under this classification.

India is a significant supplier of Amikacin formulations to the United Kingdom, accounting for 5.2% of India's total Amikacin formulation exports, valued at $21.1 million. The primary exporters from India include EMCURE PHARMACEUTICALS LIMITED and EMCURE PHARMACEUTICALS LTD, with trade values of $0.8 million and $0.3 million, respectively. The main importer in the United Kingdom is TILLOMED LABORATORIES LTD, with imports totaling $0.9 million.

Other major countries supplying Amikacin formulations to the United Kingdom include Germany and the United States. India's competitive pricing, coupled with its robust pharmaceutical manufacturing capabilities, positions it favorably against competitors. The cost-effectiveness of Indian pharmaceutical products, including Amikacin formulations, contributes to their substantial share in the United Kingdom's import market.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume. The country's pharmaceutical industry is supported by a vast network of manufacturing facilities, many of which are approved by international regulatory bodies. As of November 2024, India had 376 facilities registered with the U.S. Food and Drug Administration (FDA), including 134 dedicated to finished dosage forms (FDFs). This positions India ahead of other countries in terms of FDA-registered facilities.

The cost advantages of Indian pharmaceutical manufacturing are significant. The country's large-scale production capabilities, coupled with lower labor and operational costs, enable the production of high-quality Amikacin formulations at competitive prices. Additionally, numerous Indian facilities hold Good Manufacturing Practice (GMP) certifications from the World Health Organization (WHO) and approvals from the FDA, ensuring compliance with stringent international quality standards.

When comparing Amikacin formulations from India, China, and the European Union (EU), several factors come into play:

• Price per Unit: Indian manufacturers offer Amikacin formulations at more competitive prices compared to their Chinese and EU counterparts. This cost-effectiveness is attributed to India's efficient production processes and economies of scale.

• Quality Perception: Indian pharmaceutical products are generally well-regarded for their quality, supported by compliance with international regulatory standards. The presence of numerous WHO-GMP and FDA-approved facilities underscores this reputation.

• Regulatory Acceptance in the United Kingdom: Indian pharmaceutical products, including Amikacin formulations, are widely accepted in the UK market. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) recognizes certifications from WHO and the FDA, facilitating smoother market entry for Indian products.

• Supply Reliability Track Record: India has a strong track record of reliable pharmaceutical supply, with established logistics and distribution networks ensuring timely delivery. The country's commitment to maintaining high manufacturing standards further enhances supply chain dependability.

India's pharmaceutical industry boasts substantial manufacturing capacity for finished dosage forms, including Amikacin formulations. The country's facilities are equipped with advanced packaging and cold chain capabilities, ensuring product stability and efficacy during transportation.

In recent years, there have been no significant supply disruptions reported in the India-UK Amikacin formulation supply chain. Indian manufacturers have demonstrated consistent compliance with international regulatory standards, as evidenced by the numerous FDA and WHO-GMP approvals. While specific capacity constraints among top Indian formulation manufacturers are not widely reported, the industry's ongoing expansion and investment in infrastructure suggest a commitment to meeting global demand.

For UK buyers sourcing Amikacin formulations from India, the following strategies are recommended:

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Understand Minimum Order Quantities (MOQs): Indian manufacturers may have varying MOQs. It's essential to negotiate terms that align with your procurement needs while considering the manufacturer's production capabilities.

• Negotiate Favorable Payment Terms: Common payment terms in India-UK pharmaceutical trade include letters of credit (LC) and advance payments. Establish clear agreements to ensure mutual trust and financial security.

• Conduct Thorough Supplier Qualification: Evaluate potential suppliers based on their regulatory approvals (e.g., WHO-GMP, FDA), manufacturing capacity, quality control measures, and track record in international markets.

• Establish Clear Communication Channels: Maintain regular communication with suppliers to stay informed about production schedules, potential delays, and any changes in regulatory compliance.

By adhering to these recommendations, UK buyers can effectively source high-quality Amikacin formulations from India, ensuring both cost-effectiveness and supply reliability.

By meticulously following these guidelines, United Kingdom companies can establish robust supplier relationships with Indian manufacturers, ensuring the consistent quality and regulatory compliance of Amikacin formulations imported into the UK.